Brief: Immunicum: Phase I/II Clinical Trial On Ilixadencel Meets Primary Endpoint Of Safety
16/06/2020 07:09
June 16 (Reuters) - Immunicum AB IMMUN.ST :
* IMMUNICUM AB (PUBL) ANNOUNCES PUBLICATION OF PHASE I/II
CLINICAL
TRIAL RESULTS OF ILIXADENCEL IN GASTROINTESTINAL STROMAL TUMORS
(GIST) IN CANCER IMMUNOLOGY, IMMUNOTHERAPY
* FINAL DATA ANALYSIS SHOWED THAT TWO OUT OF SIX PATIENTS
EXHIBITED PARTIAL TUMOR RESPONSES, ACCORDING TO CHOI RESPONSE
CRITERIA (I.E. 33% OBJECTIVE RESPONSE RATE)
* PARTIAL RESPONSES OBSERVED INDICATE THAT ILIXADENCEL
CONTRIBUTED
TO THERAPEUTIC IMPACT BY OVERCOMING RESISTANCE TO TKIS IN THESE
TWO PATIENTS WITH METASTATIC DISEASE WHOSE DISEASE PREVIOUSLY
PROGRESSED ON SECOND- AND/OR THIRD-LINE TKI TREATMENT
* TRIAL MET PRIMARY ENDPOINT OF SAFETY
* ILIXADENCEL IN COMBINATION WITH DIFFERENT TYROSINE KINASE
INHIBITORS (TKIS) HAD FAVORABLE SAFETY PROFILE WITH NO
TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO SIGNS OF
AUTOIMMUNITY
Source text for Eikon: ID:nGNEbm1Q8K
Further company coverage: IMMUN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))